Home > Haematology > EHA 2021 > Myeloma and Myelofibrosis > MAIA results confirm superior efficacy of daratumumab with standard-of-care

MAIA results confirm superior efficacy of daratumumab with standard-of-care

Presented By
Prof. Thierry Facon, University of Lille, France

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
EHA 2021
Trial
Phase 3, MAIA
In patients with newly diagnosed multiple myeloma (MM), daratumumab in combination with standard-of-care (i.e. lenalidomide and dexamethasone) achieved superior outcomes in overall survival (OS), progression-free survival (PFS), and overall response rate compared with standard-of-care alone, as demonstrated by the overall survival results of the phase 3 MAIA trial. The phase 3 MAIA (NCT02252172), ALCYONE (NCT02195479), and CASSIOPEIA (NCT02541383) studies established the superior PFS of daratumumab with standard-of-care versus standard-of-care alone for patients with newly diagnosed MM [1–3]. ALCYONE also established, for the first time, an OS benefit of a daratumumab-based regimen in n...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on